Do pharmacological approaches that prevent opioid tolerance target different elements in the same regulatory machinery?
about
Striatal signal transduction and drug addictionOpioid receptor-triggered spinal mTORC1 activation contributes to morphine tolerance and hyperalgesiaMu-opioid receptors transiently activate the Akt-nNOS pathway to produce sustained potentiation of PKC-mediated NMDAR-CaMKII signaling.Contribution of adenylyl cyclase modulation of pre- and postsynaptic GABA neurotransmission to morphine antinociception and tolerance.Activators of G-protein signaling 3: a drug addiction molecular gateway.Differential tolerance to morphine antinociception in assays of pain-stimulated vs. pain-depressed behavior in rats.Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance.CaMKIIα-GluA1 Activity Underlies Vulnerability to Adolescent Binge Alcohol Drinking.Nitric oxide and zinc-mediated protein assemblies involved in mu opioid receptor signaling.Opioid-induced hyperalgesia in chronic pain patients and the mitigating effects of gabapentin.The mu-opioid receptor and the NMDA receptor associate in PAG neurons: implications in pain control.Chronic pain causes a persistent anxiety state leading to increased ethanol intake in CD1 mice.NO-released zinc supports the simultaneous binding of Raf-1 and PKCγ cysteine-rich domains to HINT1 protein at the mu-opioid receptor.Gz mediates the long-lasting desensitization of brain CB1 receptors and is essential for cross-tolerance with morphine.The histidine triad nucleotide-binding protein 1 supports mu-opioid receptor-glutamate NMDA receptor cross-regulation.Decrease of cocaine, but not heroin, self-administration and relapse by the tyrosine kinase inhibitor masitinib in male Sprague Dawley rats.
P2860
Q28392093-F7FA3532-B79F-412F-8EBA-28F68EE57B4CQ28576512-733C2024-D4C4-445E-A922-92CD76D3AF01Q33619345-C7EAB7D5-3F45-486C-9C04-3DE2D4C8D954Q33923596-F704C121-E8C8-4122-A9E1-E9A42717F979Q34235593-5EF608EE-8096-49DF-9669-82B606CAF2A2Q35039614-1F9977FD-A1AB-4813-A4DF-1A95A9CED564Q35264421-63297420-3623-43AA-B43F-5F9066063481Q36021671-C34BE70C-F788-4221-8F0D-806256789F32Q38105951-EEE8A716-8AC8-49B3-817A-88D3B402BF85Q38527782-3E303727-8B95-42D1-99D1-7EED92354D3CQ39904357-FA0E48D8-1BAE-4E3C-92CD-901621BB9F58Q40197087-9E0F00EE-A43C-41BB-8C9F-DA1FCCB3D686Q41879563-E5F22037-F97B-4E51-A47B-00860659FEF7Q41958365-32DF1EB9-187A-4C8D-8394-36114E644484Q44348688-041D3774-8FB1-4EB8-B5C8-29A7F10A2DBCQ52316247-FBD82004-C88E-4479-B643-1D6CB46F19F7
P2860
Do pharmacological approaches that prevent opioid tolerance target different elements in the same regulatory machinery?
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Do pharmacological approaches ...... the same regulatory machinery?
@ast
Do pharmacological approaches ...... the same regulatory machinery?
@en
type
label
Do pharmacological approaches ...... the same regulatory machinery?
@ast
Do pharmacological approaches ...... the same regulatory machinery?
@en
prefLabel
Do pharmacological approaches ...... the same regulatory machinery?
@ast
Do pharmacological approaches ...... the same regulatory machinery?
@en
P2093
P1476
Do pharmacological approaches ...... the same regulatory machinery?
@en
P2093
Javier Garzón
María Rodríguez-Muñoz
Pilar Sánchez-Blázquez
P304
P356
10.2174/1874473710801020222
P577
2008-06-01T00:00:00Z